Similarly, the other HSP90 inhibitor 17-AAG (17-allylamino-17-demethoxygeldanamycin, or Tanespimycin) also reduces the α-synuclein toxicity and facilitates its clearance in various experimental models of PD [71]. Here, HSP90AB1 is linked to Parkinson disease.